These authors contributed equally to this study.
Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease
Article first published online: 20 JUL 2005
British Journal of Haematology
Volume 130, Issue 4, pages 568–574, August 2005
How to Cite
Schmidt-Hieber, M., Fietz, T., Knauf, W., Uharek, L., Hopfenmüller, W., Thiel, E. and Blau, I. W. (2005), Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. British Journal of Haematology, 130: 568–574. doi: 10.1111/j.1365-2141.2005.05631.x
- Issue published online: 20 JUL 2005
- Article first published online: 20 JUL 2005
- Received 31 March 2005; accepted for publication 2 June 2005
- stem cell transplantation;
- acute GVHD;
- interleukin-2 receptor;
Acute graft-versus-host disease (aGVHD) occurs in up to 80% of patients who undergo allogeneic stem cell transplantation (SCT) and contributes significantly to transplant-related mortality (TRM). We conducted a prospective phase II trial to assess the efficacy and feasibility of treating steroid-refractory aGVHD with basiliximab, a chimaeric monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor. Basiliximab was administered intravenously at a dose of 20 mg on days 1 and 4. Twenty-three patients were enrolled between October 1999 and July 2004. We found a primary overall response rate of 82·5% with four patients (17·5%) showing a complete response and 15 patients (65%) a partial response. Six patients were again treated successfully with an IL-2 receptor antagonist because of recurrence of aGVHD. The rates of infections, chronic GVHD, malignancy recurrence and 1-year TRM following immunosuppression with basiliximab were comparable with those found with other treatment modalities for aGVHD. We conclude that basiliximab is efficient and feasible for steroid-refractory aGVHD and merits further evaluation.